Cobitolimod - InDex Pharmaceuticals

Drug Profile

Cobitolimod - InDex Pharmaceuticals

Alternative Names: Antisense oligonucleotide NF-KB-p65; DIMS-0150; Kappaproct

Latest Information Update: 06 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator InDex Pharmaceuticals
  • Class Anti-inflammatories; Antiulcers; Oligodeoxyribonucleotides
  • Mechanism of Action Toll-like receptor 9 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ulcerative colitis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Ulcerative colitis
  • Discontinued Brain oedema

Most Recent Events

  • 06 Dec 2017 Discontinued - Phase-I for Brain oedema in Sweden (Rectal) (Index Pharmaceuticals Pipeline, December 2017)
  • 01 Dec 2017 Pharmacodynamics data from a preclinical study in Ulcerative colitis released by InDex Pharmaceuticals
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Brain-oedema in Sweden (Rectal, Enema)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top